CureMed Biopharma

CureMed Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to design treatments for infectious diseases, oncology, and protein replacement therapies. Its lead program, CM-001, is an mRNA vaccine for COVID-19 that has advanced into Phase 2 clinical trials. Additionally, CureMed is developing a diverse pipeline that includes vaccines for rabies, influenza, and shingles, as well as personalized cancer vaccines. The company operates integrated R&D and GMP manufacturing facilities to support its goal of providing high-efficiency, innovative medical solutions globally.